Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands…
Opus to advance preclinical development programs for BEST1- and RHO-related retinal diseases Deal expands Opus’ addressable patient population for its…
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands…
Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients in National Cancer Institute-led Phase 2…
LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),…
BATON ROUGE, La., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice,…
XENOVIEW represents the first and only hyperpolarized MRI contrast agent ● FDA approved indication includes both adolescents and adults representing…
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the…
TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing…
– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for…